Dr. Reddy’s Laboratories Faces India's New Semaglutide Manufacturing and Testing Standards

Market snapshot: India is preparing new national manufacturing and testing standards for Semaglutide, the popular weight-loss and diabetes drug, targeting its inclusion in the Indian Pharmacopoeia Addendum 2028. This standardisation aims to establish a binding statutory benchmark for domestic generic drugmakers, including Dr. Reddy's Laboratories, who currently rely on internal protocols or foreign manuals.

Data Snapshot

• Dr. Reddy's Laboratories recorded a financial provision of ₹239.7 crore in Q1 FY27 due to semaglutide active pharmaceutical ingredient inventory and associated costs.
• The combined sales volume of generic semaglutide in India rose to 1.92 lakh units in July 2026 from 1.66 lakh units in June 2026.
• Monthly sales of Dr. Reddy's generic semaglutide brand, Obeda, more than doubled to 1.15 lakh units in July 2026 from 55,000 units in June 2026.

What's Changed

• In March 2026, Dr. Reddy's launched its generic semaglutide injection 'Obeda' in India on Day 1 of patent expiry, which subsequently saw sales double in July 2026.
• Due to an active pharmaceutical ingredient impurity detected during production scale-up, Dr. Reddy's temporarily halted commercial supplies in July 2026, leading to a ₹239.7 crore inventory write-down.
• The Indian government is transitioning from a regime of no national benchmarks to drafting an official monograph prioritized for the upcoming Indian Pharmacopoeia Addendum 2028.

Key Takeaways

• Standardised Benchmarks: The proposed monograph establishes a binding statutory benchmark for limits on purity and process-specific impurities across chemical and recombinant methods.
• Resolution Timeline: Dr. Reddy's is modifying its API synthesis process to resolve the impurity issue, planning to supply the API to its partner OneSource Specialty Pharma by early October 2026.
• Heightened Vigilance: Regulators are intensifying supervision after Interpol flagged counterfeit semaglutide batches in July 2026, with states instructed to crack down on surrogate promotions.

SAHI Perspective

The introduction of a binding statutory benchmark under the Indian Pharmacopoeia Addendum 2028 is a necessary maturation step for India's generic GLP-1 ecosystem. Currently, domestic firms rely on foreign manuals or internal protocols. A standardized national monograph will reduce testing costs, enforce uniform purity limits, and assist state regulators in curbing counterfeit products. For Dr. Reddy's, which is currently remediating an API impurity issue that triggered a ₹239.7 crore financial hit in Q1 FY27, these standards represent both a regulatory hurdle and an opportunity to restore market confidence when supplies resume.

Market Implications

Domestic pharmaceutical manufacturers will face more rigorous statutory testing but will benefit from lower compliance uncertainty and a unified protocol to detect counterfeit drugs. Regulatory enforcement will likely increase with heightened vigilance against surrogate advertising on digital media and stricter prescription monitoring.

Trading Signals

Market Bias: Neutral

The standardisation of semaglutide rules establishes a quality floor for Indian generic drugmakers. However, recent API impurities have already caused a ₹239.7 crore financial write-down for Dr. Reddy's, highlighting execution risks.

Overweight: Pharmaceuticals (Long-term)

Trigger Factors:

• Implementation of the Indian Pharmacopoeia Addendum 2028
• Resumption of Dr. Reddy's semaglutide API supplies in late October 2026
• Strict enforcement by state drug controllers against counterfeit batches

Time Horizon: Medium-term (3-12 months)

Industry Context

The global patent for Novo Nordisk's semaglutide expired in India on March 20, 2026, triggering a rush of domestic generic launches. Key players including Dr. Reddy's, Sun Pharma, and Zydus Lifesciences introduced competitive offerings. However, the lack of domestic manufacturing and testing standards has meant companies rely on varied internal protocols, which is now being addressed by the Indian Pharmacopoeia Commission's proposed monograph.

Key Risks to Watch

• Regulatory Compliance Costs: Smaller generic players may face elevated cost structures to meet the upcoming statutory limits on purity and process-specific impurities.
• Supply Chain Bottlenecks: Manufacturing complex peptide APIs and securing sterile fill-finish capacity remains highly constrained, as demonstrated by Dr. Reddy's supply delay.
• Counterfeit and Brand Risk: Interpol and CDSCO warnings regarding counterfeit batches pose safety and reputational risks for legitimate brands.

Recent Developments

Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada in April 2026 and subsequently launched its generic semaglutide injection in Canada in May 2026. However, in July 2026, the company announced a delay in commercial supplies of its semaglutide product due to an API impurity detected during production scale-up. In August 2026, Dr. Reddy's terminated its distribution agreement with Novartis India Limited, with distribution of select brands continuing only until September 30, 2026.

Closing Insight

While standardisation of manufacturing rules will build robust clinical confidence and protect consumers, it adds near-term compliance demands on generic manufacturers struggling with complex peptide synthesis pipelines.

High Performance Trading with SAHI.